This inventor holds 13 USPTO granted patents and 3 published patent applications. Top assignees: Rigel Pharmaceuticals, Incorporated, Rutgers, The State University of New Jersey, Ribogene, Inc.. Active years: 1998-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Cold Spring Harbor, NY (US) (1998)
- Montclair, NJ (US) (2000 - 2017)
Company Filing History:
8 out of 492 
3 out of 1,498 
2 out of 10 Years Active: 1998-2017
Title: **Inventor Spotlight: Michael B. Mathews**
Introduction
Michael B. Mathews is a prolific inventor based in Montclair, NJ, known for his contributions to the field of molecular biology. With a total of 13 patents to his name, Mathews has made significant strides in understanding and manipulating the processes involved in mRNA decay, leading to potential advancements in therapeutic treatments.
Latest Patents
Among his latest patents, Mathews has developed novel methods for treating Nonsense-Mediated Decay (NMD) through the inhibition of eukaryotic initiation factor 5A (eIF5A). One significant patent outlines an approach for inhibiting nonsense-mediated mRNA decay by administering a composition that prevents hypusination of eIF5A. This treatment aims to enhance gene expression of NMD-susceptible mRNA, thus mitigating the degradation typically caused by NMD.
Another critical patent focuses on the administration of an inhibitor of NMD along with a nonsense suppressor to patients suffering from NMD. This innovative method aims to block translation termination at misplaced nonsense codons, offering a promising avenue for therapeutic development in related diseases.
Career Highlights
Mathews has had an impactful career, working with industry-leading organizations such as Rigel Pharmaceuticals and Rutgers, the State University of New Jersey. His role in these institutions has been instrumental in advancing research into mRNA processes and developing innovative treatment methodologies.
Collaborations
Throughout his career, Mathews has collaborated with esteemed colleagues in the field, including Michael G. Katze and Julia C. Watson. These partnerships have bolstered his research efforts and led to significant breakthroughs in understanding the complexities of gene expression and mRNA stability.
Conclusion
Michael B. Mathews exemplifies the spirit of innovation in the scientific community. His work on patents addressing mRNA decay mechanisms demonstrates the potential for new treatments that could change the landscape of therapeutic interventions. As he continues to develop his research, the impact of his innovations will undoubtedly benefit many in the medical field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile